findmyKOL
Clinical trialNCT06712810RecruitingPhase 1Interventional

Q702 for the Treatment of Patients With Hematologic Malignancies

SponsorMayo ClinicEnrollment46Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant HistiocytosisPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPrimary Central Nervous System LymphomaPrimary Cutaneous T-Cell Non-Hodgkin Lymphoma+31 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic in Arizona

    Scottsdale, Arizona, United States

    Talal Hilal, MD
    Recruiting
  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

    Jithma P. Abeykoon, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Axl/Mer/CSF1R Inhibitor Q702
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Aug 2025
Primary completion
15 Sept 2030
Completion
15 Sept 2030
Last update posted
10 Oct 2025
Registered enrollment
46
Registry id
NCT06712810
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.